Skip to main content
Skip to primary sidebar
Skip to footer

240.243.1201
info@glycomimetics.com

Careers
Contact Us

About Us
Patients
- Clinical Trials
Pipeline
Science
Collaborations
Investors
Careers
Contact Us
Search

Technology & Publications

Scientific Publications
Intellectual Property
Platform & Research

Primary Sidebar

News

July 25, 2024
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

June 4, 2024
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 29, 2024
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 6, 2024
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Footer

Questions?

Contact GlycoMimetics Today

© GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans

Site Map | Terms of Use | Privacy | Contact Us